# Post-Transcriptional Modification Integration for Ligand–Receptor Cellular Network Inference

**Authors:** Pierre Giroux, Morgan Maillard, Jacques Colinge

PMC · DOI: 10.1016/j.mcpro.2025.101493 · Molecular & Cellular Proteomics : MCP · 2025-12-19

## TL;DR

This paper introduces a new method to improve the accuracy of predicting cell communication by incorporating protein modifications.

## Contribution

The novel contribution is integrating post-translational modifications into ligand–receptor interaction inference using an extended BulkSignalR framework.

## Key findings

- PTM integration reduces false positives in pathway activation predictions.
- The method reveals context-specific signaling in cancer datasets.
- The framework supports all types of PTMs and works with bulk and single-cell data.

## Abstract

Cell–cell communications are widely explored to understand tissue homeostasis and diseases. Numerous computational tools have been developed to infer cellular interactions from transcriptomic or proteomic expression data. However, proteins often carry post-translational modifications (PTMs) that can induce conformational switches and alter their functional properties. A key challenge remains to incorporate PTM data in the inference and analysis of cellular interactions. Here, we propose an extension of our previously published tool BulkSignalR to integrate PTM information in ligand–receptor interactions and downstream pathway predictions. This new functionality is compatible with bulk and single-cell data, and it supports all types of PTMs. Based on two illustrative datasets, we show that this new feature provides deeper insights into biological pathway regulation and that PTM integration helps reduce false-positive results occasionally produced by standard approaches.

•Extending BulkSignalR to integrate post-translational modifications (PTMs) into ligand–receptor interaction inference.•PTM integration improves accuracy and confidence in pathway activation prediction.•Application to two cancer datasets reveals context-specific signaling.•Framework supports all types of PTMs.

Extending BulkSignalR to integrate post-translational modifications (PTMs) into ligand–receptor interaction inference.

PTM integration improves accuracy and confidence in pathway activation prediction.

Application to two cancer datasets reveals context-specific signaling.

Framework supports all types of PTMs.

We developed an extension of BulkSignalR to integrate post-translational modification data in the inference of ligand–receptor interactions and downstream signaling pathways. Applied to laryngeal squamous cell carcinoma and renal carcinoma datasets, this approach refines pathway activation analysis, reduces false positives, and reveals context-dependent signaling mechanisms. By combining proteomic and post-translational modification data, it provides a more mechanistic understanding of cellular communication and regulatory processes across biological contexts.

## Linked entities

- **Diseases:** laryngeal squamous cell carcinoma (MONDO:0005595), renal carcinoma (MONDO:0005206)

## Full-text entities

- **Genes:** PRKCZ (protein kinase C zeta) [NCBI Gene 5590] {aka PKC-ZETA, PKC2}, STAT6 (signal transducer and activator of transcription 6) [NCBI Gene 6778] {aka D12S1644, HIES6, IL-4-STAT, STAT6B, STAT6C}, GAB1 (GRB2 associated binding protein 1) [NCBI Gene 2549] {aka DFNB26}, PRKCA (protein kinase C alpha) [NCBI Gene 5578] {aka AAG6, PKC-alpha, PKCA, PKCI+/-, PKCalpha}, DCN (decorin) [NCBI Gene 1634] {aka CSCD, DSPG2, PG40, PGII, PGS2, SLRR1B}, TGFB1 (transforming growth factor beta 1) [NCBI Gene 7040] {aka CAEND1, CED, DPD1, IBDIMDE, LAP, TGF-beta1}, FGA (fibrinogen alpha chain) [NCBI Gene 2243] {aka AMYLD2, Fib2}, PXN (paxillin) [NCBI Gene 5829], KDR (kinase insert domain receptor) [NCBI Gene 3791] {aka CD309, FLK1, VEGFR, VEGFR2}, STAT3 (signal transducer and activator of transcription 3) [NCBI Gene 6774] {aka ADMIO, ADMIO1, APRF, HIES}, MAPK1 (mitogen-activated protein kinase 1) [NCBI Gene 5594] {aka ERK, ERK-2, ERK2, ERT1, MAPK2, NS13}, VEGFA (vascular endothelial growth factor A) [NCBI Gene 7422] {aka L-VEGF, MVCD1, VEGF, VPF}, MAPK3 (mitogen-activated protein kinase 3) [NCBI Gene 5595] {aka ERK-1, ERK1, ERT2, HS44KDAP, HUMKER1A, P44ERK1}, RET (ret proto-oncogene) [NCBI Gene 5979] {aka CDHF12, CDHR16, HSCR1, MEN2A, MEN2B, MTC1}, INHBA (inhibin subunit beta A) [NCBI Gene 3624] {aka EDF, FRP}, TGFBR1 (transforming growth factor beta receptor 1) [NCBI Gene 7046] {aka AAT5, ACVRLK4, ALK-5, ALK5, ESS1, LDS1}, SMAD4 (SMAD family member 4) [NCBI Gene 4089] {aka DPC4, JIP, MADH4, MYHRS}, MAP2K2 (mitogen-activated protein kinase kinase 2) [NCBI Gene 5605] {aka CFC4, MAPKK2, MEK2, MKK2, PRKMK2}, UBA52 (ubiquitin A-52 residue ribosomal protein fusion product 1) [NCBI Gene 7311] {aka CEP52, HUBCEP52, L40, RPL40}, KAT2B (lysine acetyltransferase 2B) [NCBI Gene 8850] {aka CAF, P/CAF, PCAF}, PRKCD (protein kinase C delta) [NCBI Gene 5580] {aka ALPS3, CVID9, MAY1, PKCD, nPKC-delta}, TXK (TXK tyrosine kinase) [NCBI Gene 7294] {aka BTKL, PSCTK5, PTK4, RLK, TKL}, PIK3CB (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta) [NCBI Gene 5291] {aka P110BETA, PI3K, PI3KBETA, PIK3C1}, SLTM (SAFB like transcription modulator) [NCBI Gene 79811] {aka Met}
- **Diseases:** LRIs (MESH:C563663), CPTAC (MESH:D009369), Clear cell renal cell carcinoma (MESH:D002292), LSCC (MESH:D002294), laryngeal squamous cell carcinoma (MESH:D000077195), Renal Cancer (MESH:D007680)
- **Chemicals:** P (MESH:D010758), CBL S-483 (-), peptides (MESH:D010455), Sunitinib (MESH:D000077210)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12933558/full.md

## Figures

7 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12933558/full.md

## References

44 references — full list in the complete paper: https://tomesphere.com/paper/PMC12933558/full.md

---
Source: https://tomesphere.com/paper/PMC12933558